References
- Parry CH. Collections from the Unpublished Medical Writings of the Late Caleb Hillier Parry. Vol. 1. London: Underwoods; 1825.
- Loriaux DL. Caleb Hillier Parry (1755–1822). In: A Biographical History of Endocrinology. John Wiley & Sons, Ltd; 2016:77–81. doi:https://doi.org/10.1002/9781119205791.ch20.
- Ing EB, Madjedi K, Hurwitz JJ, Nijhawan N, Oestreicher J, Torun N. Nomenclature: thyroid-associated orbitopathy, Graves ophthalmopathy, or thyroid eye disease? Can J Ophthalmol. 2021;56(1):e22–e24. doi:https://doi.org/10.1016/j.jcjo.2020.06.004.
- Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab. 2012;26(3):273–279. doi:https://doi.org/10.1016/j.beem.2011.10.005.
- Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf). 1993;38(4):367–372. doi:https://doi.org/10.1111/j.1365-2265.1993.tb00516.x.
- Sikder S, Weinberg RS. Thyroid eye disease: pathogenesis and treatment. Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd. 2010;224(4):199–203. doi:https://doi.org/10.1159/000260224.
- Perros P, Neoh C, Dickinson J. Thyroid eye disease. BMJ. 2009;338:b560. doi:https://doi.org/10.1136/bmj.b560.
- Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123(2):183.e1–9. doi:https://doi.org/10.1016/j.amjmed.2009.06.030.
- Yin X, Latif R, Bahn R, Davies TF. Genetic profiling in Graves’ disease: further evidence for lack of a distinct genetic contribution to Graves’ ophthalmopathy. Thyroid Off J Am Thyroid Assoc. 2012;22(7):730–736. doi:https://doi.org/10.1089/thy.2012.0007.
- Wallang BS, Kekunnaya R, Granet D. Strabismus surgery in thyroid-related eye disease: strategic decision making. Curr Ophthalmol Rep. 2013;1(4):218–228. doi:https://doi.org/10.1007/s40135-013-0027-z.
- Bahn RS. Understanding the immunology of Graves’ ophthalmopathy. Is it an autoimmune disease? Endocrinol Metab Clin North Am. 2000;29(2):287–296, vi. doi:https://doi.org/10.1016/s0889-8529(05)70132-8.
- Smith TJ, Hegedüs L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):291–302. doi:https://doi.org/10.1016/j.beem.2011.10.002.
- McAlinden C. An overview of thyroid eye disease. Eye Vis. 2014;1. doi:https://doi.org/10.1186/s40662-014-0009-8.
- Verity DH, Rose GE. Acute thyroid eye disease (TED): principles of medical and surgical management. Eye Lond Engl. 2013;27(3):308–319. doi:https://doi.org/10.1038/eye.2012.284.
- Denniston AKO, Murray PI. Oxford Handbook of Ophthalmology. 4th, New to this Edition ed. Oxford University Press; 2018.
- Eckstein A, Esser J, Oeverhaus M, Saeed P, Jellema HM. Surgical Treatment of Diplopia in Graves Orbitopathy Patients. Ophthal Plast Reconstr Surg. 2018;34(4SSuppl 1):S75–S84. doi:https://doi.org/10.1097/IOP.0000000000001148.
- Kuriyan AE, Woeller CF, O’Loughlin CW, Phipps RP, Feldon SE. Orbital Fibroblasts From Thyroid Eye Disease Patients Differ in Proliferative and Adipogenic Responses Depending on Disease Subtype. Invest Ophthalmol Vis Sci. 2013;54(12):7370–7377. doi:https://doi.org/10.1167/iovs.13-12741.
- Kalmann R, Mourits MP. Late recurrence of unilateral graves orbitopathy on the contralateral side. Am J Ophthalmol. 2002;133(5):727–729. doi:https://doi.org/10.1016/s0002-9394(02)01390-9.
- Dyer JA. The oculorotary muscles in Graves’ disease. Trans Am Ophthalmol Soc. 1976;74:425–456.
- Sugar HS. Management of eye movement restriction (particularly vertical) in dysthyroid myopathy. Ann Ophthalmol. 1979;11:1305–1308, 1311–1312, 1314–1318.
- Dagi LR, Elliott AT, Roper-Hall G, Cruz OA. Thyroid eye disease: honing your skills to improve outcomes. J AAPOS. 2010;14(5):425–431. doi:https://doi.org/10.1016/j.jaapos.2010.07.005.
- Patel P, Khandji J, Kazim M. Recurrent Thyroid Eye Disease. Ophthal Plast Reconstr Surg. 2015;31(6):445–448. doi:https://doi.org/10.1097/IOP.0000000000000371.
- Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med. 1993;329(20):1468–1475. doi:https://doi.org/10.1056/NEJM199311113292007.
- Soeters MR, van Zeijl CJJ, Boelen A, et al. Optimal management of Graves orbitopathy: a multidisciplinary approach. Neth J Med. 2011;69(7):302–308.
- Weis E, Heran MKS, Jhamb A, et al. Quantitative computed tomographic predictors of compressive optic neuropathy in patients with thyroid orbitopathy: a volumetric analysis. Ophthalmology. 2012;119(10):2174–2178. doi:https://doi.org/10.1016/j.ophtha.2012.04.021.
- Terwee C, Gerding M, Dekker F, Prummel M, Wiersinga W. Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82(7):773–779. doi:https://doi.org/10.1136/bjo.82.7.773.
- Fayers T, Dolman PJ. Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol. 2011;95(12):1670–1674. doi:https://doi.org/10.1136/bjophthalmol-2011-300487.
- Bothun ED, Scheurer RA, Harrison AR, Lee MS. Update on thyroid eye disease and management. Clin Ophthalmol Auckl NZ. 2009;3:543–551.
- Frueh BR, Musch DC, Garber FW. Lid retraction and levator aponeurosis defects in Graves’ eye disease. Ophthalmic Surg. 1986;17:216–220.
- Alves M, Miranda A, Narciso MR, Mieiro L, Fonseca T. Diplopia: a diagnostic challenge with common and rare etiologies. Am J Case Rep. 2015;16:220–223. doi:https://doi.org/10.12659/AJCR.893134.
- Amin S, Aung M, Gandhi FR, Escobar JAP, Gulraiz A, Malik BH. Myasthenia Gravis and its Association With Thyroid Diseases. Cureus. 2020;12(9). doi:https://doi.org/10.7759/cureus.10248.
- Yang DD, Gonzalez MO, Durairaj VD. Medical management of thyroid eye disease. Saudi J Ophthalmol. 2011;25(1):3–13. doi:https://doi.org/10.1016/j.sjopt.2010.10.001.
- Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338(2):73–78. doi:https://doi.org/10.1056/NEJM199801083380201.
- Dolman PJ. Grading severity and activity in thyroid eye disease. Ophthal Plast Reconstr Surg. 2018;34(4S):S34. doi:https://doi.org/10.1097/IOP.0000000000001150.
- Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT. Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf). 2005;63(4):395–402. doi:https://doi.org/10.1111/j.1365-2265.2005.02352.x.
- Kohn JC, Rootman DB, Liu W, Goh AS, Hwang CJ, Goldberg RA. Hyaluronic acid gel injection for upper eyelid retraction in thyroid eye disease: functional and dynamic high-resolution ultrasound evaluation. Ophthal Plast Reconstr Surg. 2014;30(5):400–404. doi:https://doi.org/10.1097/IOP.0000000000000130.
- Rajendram R, Bunce C, Adams GGW, Dayan CM, Rose GE. Smoking and strabismus surgery in patients with thyroid eye disease. Ophthalmology. 2011;118(12):2493–2497. doi:https://doi.org/10.1016/j.ophtha.2011.06.003.
- Marquez SD, Lum BL, McDougall IR, et al. Long-term results of irradiation for patients with progressive GRAVES’ ophthalmopathy. Int J Radiat Oncol. 2001;51(3):766–774. doi:https://doi.org/10.1016/S0360-3016(01)01699-6.
- Thornton J, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: a systematic review. Eye. 2007;21(9):1135–1145. doi:https://doi.org/10.1038/sj.eye.6702603.
- Khong JJ, Goldstein RF, Sanders KM, et al. Serum selenium status in Graves’ disease with and without orbitopathy: a case-control study. Clin Endocrinol (Oxf). 2014;80(6):905–910. doi:https://doi.org/10.1111/cen.12392.
- Lantz M, Vondrichova T, Parikh H, et al. Overexpression of immediate early genes in active Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2005;90(8):4784–4791. doi:https://doi.org/10.1210/jc.2004-2275.
- Lantz M, Calissendorff J, Träisk F, et al. Adjuvant Treatment of Graves’ Disease with Diclofenac: safety, Effects on Ophthalmopathy and Antibody Concentrations. Eur Thyroid J. 2016;5(1):50–56. doi:https://doi.org/10.1159/000443373.
- Bloise W, Mimura LY, Moura J, Nicolau W. Treatment of mild to moderate Graves’ ophthalmopathy with sodium diclofenac: a pilot study. Arq Bras Endocrinol Metabol. 2011;55(9):692–695. doi:https://doi.org/10.1590/s0004-27302011000900004.
- Bartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454–4463. doi:https://doi.org/10.1210/jc.2012-2389.
- Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234–5240. doi:https://doi.org/10.1210/jc.2005-0148.
- Ebner R, Devoto MH, Weil D, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88(11):1380–1386. doi:https://doi.org/10.1136/bjo.2004.046193.
- Strianese D, Iuliano A, Ferrara M, et al. Methotrexate for the treatment of thyroid eye disease. J Ophthalmol. 2014;2014:128903. doi:https://doi.org/10.1155/2014/128903.
- Rajendram R, Taylor PN, Wilson VJ, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(4):299–309. doi:https://doi.org/10.1016/S2213-8587(18)30021-4.
- Ostrowski RA, Bussey MR, Shayesteh Y, Jay WM. Rituximab in the treatment of thyroid eye disease: a review. Neuro-Ophthalmol. 2015;39(3):109–115. doi:https://doi.org/10.3109/01658107.2015.1039140.
- Kahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986;16(5):415–422. doi:https://doi.org/10.1111/j.1365-2362.1986.tb01016.x.
- Shen S, Chan A, Sfikakis PP, et al. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Surv Ophthalmol. 2013;58(3):252–265. doi:https://doi.org/10.1016/j.survophthal.2012.10.006.
- Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol Baltim Md 1950. 2008;181(6):4397–4405. doi:https://doi.org/10.4049/jimmunol.181.6.4397.
- Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–1761. doi:https://doi.org/10.1056/NEJMoa1614949.
- Roos JCP, Hyry HI, Murthy R. Teprotumumab for active thyroid eye disease. N Engl J Med. 2020;382(20):1959. doi:https://doi.org/10.1056/NEJMc2002754.
- Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit Amst Neth. 2021;1–8. Published online June 1. doi:https://doi.org/10.1080/01676830.2021.1933081.
- Ozzello DJ, Kikkawa DO, Korn BS. Early experience with teprotumumab for chronic thyroid eye disease. Am J Ophthalmol Case Rep. 2020;19:100744. doi:https://doi.org/10.1016/j.ajoc.2020.100744.
- Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye Lond Engl. 2021. Published online July 9. doi:https://doi.org/10.1038/s41433-021-01593-z.
- Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181–190. doi:https://doi.org/10.1016/j.ajo.2018.07.038.
- Costa PG, Saraiva FP, Pereira IC, Monteiro MLR, Matayoshi S. Comparative study of Botox ® injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage. Eye. 2009;23(4):767–773. doi:https://doi.org/10.1038/eye.2008.165.
- Mukamal R. New drug treats thyroid eye disease without surgery. American Academy of Ophthalmology. Published February 5, 2020. Accessed August 20, 2021. https://www.aao.org/eye-health/news/tepezza-nonsurgical-treatment-thyroid-eye-disease.
- Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology. 2002;109(6):1183–1187. doi:https://doi.org/10.1016/s0161-6420(02)01041-2.
- Granet DB, Hodgson N, Godfrey KJ, et al. Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2016;254(5):999–1003. doi:https://doi.org/10.1007/s00417-016-3281-6.
- Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. 1991;14(10):853–860. doi:https://doi.org/10.1007/BF03347943.
- Wakelkamp IMMJ, Tan H, Saeed P, et al. Orbital irradiation for Graves’ ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology. 2004;111(8):1557–1562. doi:https://doi.org/10.1016/j.ophtha.2003.12.054.
- Strianese D. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease. Curr Opin Ophthalmol. 2017;28(5):505–513. doi:https://doi.org/10.1097/ICU.0000000000000402.
- Cho YY, Chung YJ. Vitamin D supplementation does not prevent the recurrence of Graves’ disease. Sci Rep. 2020;10(1):16. doi:https://doi.org/10.1038/s41598-019-55107-9.
- Amemiya T. Long-term indomethacin treatment of ophthalmopathies after Basedow disease in general practice. Klin Monatsbl Augenheilkd. 1982;181(4):286–289. doi:https://doi.org/10.1055/s-2008-1055220.
- Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010;95(3):1333–1337. doi:https://doi.org/10.1210/jc.2009-2130.
- Allen RC, Bradley EA, Fante RG, Lucarelli MJ. A perspective on the current role of teprotumumab in treatment of thyroid eye disease. Ophthalmology. 2021;S0161-6420(21)00167–6. Published online April 3. doi:https://doi.org/10.1016/j.ophtha.2021.03.006.
- Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth Factor-1 receptor by T cells from patients with Graves’ disease may carry functional consequences for disease pathogenesis. J Immunol. 2007;178(5):3281–3287. doi:https://doi.org/10.4049/jimmunol.178.5.3281.
- Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves’ disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol Baltim Md 1950. 2008;181(8):5768–5774. doi:https://doi.org/10.4049/jimmunol.181.8.5768.
- Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341–352. doi:https://doi.org/10.1056/NEJMoa1910434.
- Kim S, Patzek S. Teprotumumab for active thyroid eye disease. N Engl J Med. 2020;382(20):1958–1959. doi:https://doi.org/10.1056/NEJMc2002754.
- Sears CM, Wang Y, Bailey LA, et al. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study. Am J Ophthalmol Case Rep. 2021;23:101111. doi:https://doi.org/10.1016/j.ajoc.2021.101111.
- Träisk F, Tallstedt L. Thyroid associated ophthalmopathy: botulinum toxin A in the treatment of upper eyelid retraction–a pilot study. Acta Ophthalmol Scand. 2001;79(6):585–588. doi:https://doi.org/10.1034/j.1600-0420.2001.790608.x.
- Wu X, Lin N, Ai L, Wang J, Yan L. The application of botulinum toxin A in the treatment of restrictive strabismus in thyroid associated ophthalmopathy. Zhonghua Yan Ke Za Zhi Chin J Ophthalmol. 2006;42:1063–1067.
- Gorman Ca, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology. 2001;108(9):1523–1534. doi:https://doi.org/10.1016/s0161-6420(01)00632-7.
- Smith TJ, Hegedüs L. Graves’ Disease. N Engl J Med. 2016;375(16):1552–1565. doi:https://doi.org/10.1056/NEJMra1510030.
- Kahaly GJ, Riedl M, König J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287–298. doi:https://doi.org/10.1016/S2213-8587(18)30020-2.
- Saeed P, Tavakoli Rad S, Bisschop PHLT. Dysthyroid Optic Neuropathy. Ophthal Plast Reconstr Surg. 2018;34(4S):S60. doi:https://doi.org/10.1097/IOP.0000000000001146.
- Maamari RN, Couch SM. Combined orbital decompression and strabismus surgery in thyroid eye disease. Int Ophthalmol Clin. 2021;61(2):127–136. doi:https://doi.org/10.1097/IIO.0000000000000350.
- McCracken MS, Del Prado JD, Granet DB, Levi L, Kikkawa DO. Combined eyelid and strabismus surgery: examining conventional surgical wisdom. J Pediatr Ophthalmol Strabismus. 2008;45(4):220–224;quiz 225–226. doi:https://doi.org/10.3928/01913913-20080701-11.
- Naik MN, Nair AG, Gupta A, Kamal S. Minimally invasive surgery for thyroid eye disease. Indian J Ophthalmol. 2015;63(11):847–853. doi:https://doi.org/10.4103/0301-4738.171967.
- Rootman DB. Orbital decompression for thyroid eye disease. Surv Ophthalmol. 2018;63(1):86–104. doi:https://doi.org/10.1016/j.survophthal.2017.03.007.
- Kikkawa DO, Pornpanich K, Cruz RC, Levi L, Granet DB. Graded orbital decompression based on severity of proptosis. Ophthalmology. 2002;109(7):1219–1224. doi:https://doi.org/10.1016/s0161-6420(02)01068-0.
- Shorr N, Neuhaus RW, Baylis HI. Ocular motility problems after orbital decompression for dysthyroid ophthalmopathy. Ophthalmology. 1982;89(4):323–328. doi:https://doi.org/10.1016/s0161-6420(82)34793-4.
- Schotthoefer EO, Wallace DK. Strabismus associated with thyroid eye disease. Curr Opin Ophthalmol. 2007;18(5):361–365. doi:https://doi.org/10.1097/ICU.0b013e32827038f2.
- Fells P, Kousoulides L, Pappa A, Munro P, Lawson J. Extraocular muscle problems in thyroid eye disease. Eye. 1994;8(5):497–505. doi:https://doi.org/10.1038/eye.1994.125.
- Dagi L. Strabismus from Thyroid Eye Disease: observations from the Field. AAPOS Webinar: Adult Strabismus. Published online August 19, 2020.
- Sharma P, Reinecke RD. Single-stage adjustable strabismus surgery for restrictive strabismus. J AAPOS. 2003;7(5):358–362. doi:https://doi.org/10.1016/s1091-8531(03)00212-x.
- Kerr NC. The role of thyroid eye disease and other factors in the overcorrection of hypotropia following unilateral adjustable suture recession of the inferior rectus (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2011;109:168–200.
- Kushner BJ. An evaluation of the semiadjustable suture strabismus surgical procedure. J AAPOS. 2004;8(5):481–487. doi:https://doi.org/10.1016/j.jaapos.2004.07.005.
- Wan MJ, Hunter DG. Complications of strabismus surgery: incidence and risk factors. Semin Ophthalmol. 2014;29(5–6):421–428. doi:https://doi.org/10.3109/08820538.2014.959190.
- Ellis EM, Kinori M, Robbins SL, Granet DB. Pulled-in-two syndrome: a multicenter survey of risk factors, management and outcomes. J AAPOS. 2016;20(5):387–391. doi:https://doi.org/10.1016/j.jaapos.2016.06.004.
- Huang C-Y, Lin H-C, Yang M-L. Necrotizing scleritis after strabismus surgery in thyroid eye disease. J AAPOS. 2013;17(5):535–536. doi:https://doi.org/10.1016/j.jaapos.2013.04.010.
- Kazim M, Gold KG. A review of surgical techniques to correct upper eyelid retraction associated with thyroid eye disease. Curr Opin Ophthalmol. 2011;22(5):391–393. doi:https://doi.org/10.1097/ICU.0b013e3283499433.
- Ben Simon GJ, Mansury AM, Schwarcz RM, Modjtahedi S, McCann JD, Goldberg RA. Transconjunctival Müller muscle recession with levator disinsertion for correction of eyelid retraction associated with thyroid-related orbitopathy. Am J Ophthalmol. 2005;140(1):94–99. doi:https://doi.org/10.1016/j.ajo.2005.02.034.
- Nimitwongsakul A, Zoumalan CI, Kazim M. Modified full-thickness blepharotomy for treatment of thyroid eye disease. Ophthal Plast Reconstr Surg. 2013;29(1):44–47. doi:https://doi.org/10.1097/IOP.0b013e318275b5e2.